Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB Study in Patients with Chronic Hepatitis B Infection
Shots:
- Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989- JNJ-6379- NA- and/or PBO in 450 patients with chronic hepatitis B virus infection for 48 wks.- evaluating its safety and efficacy
- Additionally- in Oct 2018 Arrowhead collaborated with Janssen to develop and commercialize Arrowhead’s ARO-HBV
- JNJ-3989 (SC) is an investigational antiviral liver-targeting candidate designed to treat chronic HBV infection via the ribonucleic acid interference (RNAi) mechanism. JNJ-6379 (PO) is capsid assembly modulator of the class that forms normal capsid structures (CAM-N)
Click here to read full press release/ article |
Ref: Arrowhead Pharmaceuticals | Image: Janssen
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com